




RealRate

PHARMACEUTICAL 2018

Onconova Therapeutics Inc. Rank 329 of 342





RealRate

PHARMACEUTICAL 2018

Onconova Therapeutics Inc. Rank 329 of 342



The relative strengths and weaknesses of Onconova Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Onconova Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Onconova Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 239% points.

The company's Economic Capital Ratio, given in the ranking table, is -411%, being 456% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	4,903
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,976
Liabilities, Non-Current	0
Other Assets	12
Other Compr. Net Income	34
Other Expenses	-1,615
Other Liabilities	5,864
Other Net Income	30
Other Revenues	787
Property and Equipment	64
Research and Development	19,119
Selling, General and Administrative Expense	7,405

Output Variable	Value in 1000 USD
Assets	4,979
Liabilities	15,840
Expenses	24,909
Revenues	787
Stockholders Equity	-10,861
Net Income	-24,092
Comprehensive Net Income	-24,075
Economic Capital Ratio	-411%